主治醫師：劉蓓麗

論文及學術著作

• Chen LY, Chen HY, Lai HC, Lin SF, Wen KC, Darmawi, Liew PL. The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clinical outcomes. Taiwan J Obstet Gynecol. 2025 Jan;64(1):110-119.
• Chen LY, Chou YT, Liew PL, Chu LH, Wen KC, Lin SF, Weng YC, Wang HC, Su PH, Lai HC. In vitro drug testing using patient-derived ovarian cancer organoids. J Ovarian Res. 2024 Oct 2;17(1):194. doi: 10.1186/s13048-024-01520-2.
• Chen LY, Shen YA, Chu LH, Su PS, Wang HC, Weng YC, Lin SF, Wen KC, Liew PL, Lai HC. Active DNA Demethylase, TET1, Increased Oxidative Phophorylation and Sensitized Ovarian Cancer Stem Cells to Mitochondrial Complex I Inhibitor. Antioxidants. 2024; 13 (6): 735.
• Chen SH, Miser JS, Liew PL, Chen BJ, Liu YL. Pulmonary lymphoepithelioma-like carcinoma: A complication of Epstein-Barr virus in a teenager. J Microbiol Immunol Infect. 2023 Aug;56(4):886-888.
• Lin CM, Lin SF, Lee YC, Lai HC, Liew PL. Association of immunohistochemical profiles with histotypes in endometrial carcinomas. Taiwan J Obstet Gynecol. 2022;61(5):823-829.
• Darmawi, Chen LY, Su PH, Liew PL, Wang HC, Weng YC, Huang RL, Lai HC. BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. Int J Mol Sci. 2022 Jun 28;23(13):7158.
• Lin RK, Su CM, Lin SY, Thu LTA, Liew PL, Chen JY, Tzeng HE, Liu YR, Chang TH, Lee CY, Hung CS. Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer. Mol Med. 2022 Jun 17;28(1):67.
• Chu LH, Liao CC, Liew PL, Chen CW, Su PH, Wen KC, Lai HC, Huang RL, Chen LY. Epigenomic Analysis Reveals the KCNK9 Potassium Channel as a Potential Therapeutic Target for Adenomyosis. Int J Mol Sci. 2022 May 26;23(11):5973.
• Chen WY, Wen YC, Lin SR, Yeh HL, Jiang KC, Cehn WH, Lin YS, Zhang Q, Liew PL, Hsiao M, Huang J, Liu YN. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Communication Biology. 2021 Jan 4;4(1):22.
• Lin YC, Wen KC, Sung PL, Chou YT, Liew PL, Chen LY, Huang RL, Lai HC, Chang LT. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res. 2020 Dec 8;13(1):143.
• Chang SC, Liew PL, Ansar M, Lin SY, Wang SC, Hung CS, Chen JY, Jain S, Lin RK. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction. Clinical Epigenetics. 2020 (12):67-83.